Co., Ltd. ('LongBio'), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An investigational oral drug lowered lipoprotein(a) ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical ...

Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. In a statement, the company said the ...

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...

SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer ...